TXTomas Xuclà-Ferrarons

Tomas Xuclà-Ferrarons

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tomas Xuclà-Ferrarons has a total of 63 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Eicosapentaenoic acid blood status and outcomes in intracerebral haemorrhage

    by Tomàs Xuclà-Ferrarons, Iolanda Lázaro, Carme Gubern-Mérida, Joan Martínez-Sancho, William S. Harris, Mikel Terceño, Antonia Escanellas, Joaquin Serena, Aleix Sala-Vila, Yolanda Silva

  • Open Access

    Temporal Profile of Soluble TLR4 and its Association with Intracerebral Haemorrhage Expansion

    by Maria Lucas-Parra, Carme Gubern-Mérida, Sofia Dávila, Tomàs Xuclà-Ferrarons, Joan Martínez, Saima Bashir, Alan Murillo, Víctor Vera-Monge, Juan Álvarez-Cienfuegos, Laia Carballo-Perich, et al.

    Inflammation contributes to haematoma expansion (HE) and poor prognosis in spontaneous intracerebral haemorrhage (ICH). This study aimed to characterise the temporal profile of soluble Toll-like receptor 4 (sTLR4) during the hyperacute and acute phases of ICH and to evaluate its association with HE. Serum sTLR4 levels were measured at admission, 24 and 72 h from 99 patients with primary hemispheric ICH within 12 h of symptom onset, and at baseline from 39 non-stroke controls using enzyme-linked immunosorbent assay (ELISA). Longitudinal sTLR4 fluctuations were evaluated through linear mixed-effects models. Independent HE prognosticators were identified using multivariable logistic regression, and model performance was assessed via the area under the receiver operating characteristic curve (AUC-ROC). ICH patients exhibited significantly higher baseline sTLR4 levels than controls, which declined over time and were not associated with clinical variables. Notably, patients with HE demonstrated higher admission sTLR4 levels than those without HE (2.50 [95% CI: 1.84–3.16] vs. 1.62 [95% CI: 1.22–2.02] ng/mL, p = 0.027). Furthermore, while the non-HE group showed a rapid decrease within the first 24 h, the HE group maintained elevated levels with a more gradual decline. A multivariable model incorporating baseline ICH volume and sTLR4 levels achieved an AUC of 0.829, with positive and negative predictive values of 70.8% and 90.1%, respectively. These findings suggest that TLR4 may be involved in the pathophysiology of HE, and the combination of baseline ICH volume and sTLR4 levels could serve as a useful tool to stratify patients into low- and high-risk groups for HE.

  • Emergent Carotid Artery Stenting in Patients With Acute Ischemic Stroke With Tandem Lesions

    by Garbiñe Ezcurra-Díaz, Pere Cardona, Noelia Rodriguez-Villatoro, Antonio Doncel-Moriano Cubero, Belen Flores-Pina, Georgina Laia Figueras-Aguirre, Isabel Fernández-Pérez, Tomas Xuclà-Ferrarons, Francisco Purroy, Alan Flores, et al.

    Management of carotid lesions during endovascular therapy (EVT) in patients with acute ischemic stroke (AIS) due to tandem lesions (TL) remains controversial, and long-term prognosis data are scarce. We evaluated 90-day and 1-year follow-up outcomes of emergent carotid artery stenting (eCAS) vs non-eCAS in these patients. Data from a prospective mandatory population-based registry of Code Stroke in Catalonia (Spain) between 2017 and 2023 were analyzed. Patients with large vessel occlusion and ipsilateral ≥50% atheromatous cervical internal carotid artery (ICA) stenosis undergoing EVT were identified. eCAS and non-eCAS groups were compared. The primary outcome was the shift in the modified Rankin Scale (mRS) score at 90 days and 1 year of follow-up, adjusted using inverse probability of treatment weighting. Stratified analyses in predefined key subgroups according to sex, age, degree of ICA stenosis, Alberta Stroke Program Early CT Score, baseline NIH Stroke Scale, and previous IV thrombolysis were performed. Secondary outcomes included successful recanalization (modified Thrombolysis In Cerebral Infarction ≥2b), 90-day favorable functional outcome (mRS 0-2), hemorrhagic transformation (HT), and 90-day mortality. Among 578 patients included (mean age 70.2 years old, 140 [24.2%] women), 344 patients (59.5%) underwent eCAS. eCAS was associated with a better functional outcome at 90 days (common odds ratio [cOR] for a 1-point less on the mRS score 1.47, 95% CI 1.20-1.82, p < 0.001) and 1 year of follow-up (cOR of 1.47, 95% CI 1.16-1.85, p = 0.001), and with higher successful recanalization rates (OR 4.28, 95% CI 2.61-7.0, p < 0.001), without increasing HT risk or mortality. The benefit of eCAS was consistent in both moderate (50%-69%) and severe (≥70%) ICA stenosis subgroups. Among the eCAS group, patients under dual antiplatelet therapy at 24 hours showed higher rates of favorable functional outcome (54.6% vs 22.9%, p < 0.001). Potential treatment effect differences were observed for women and older patients. In this population-based study of patients with AIS due to TL, eCAS was associated with a better mid-term and long-term functional outcome without safety concerns, even in moderate ICA stenosis. Limitations include the observational design and possible unmeasured confounders. Further studies are needed to explore the mechanisms underlying the differential effects of eCAS in women and older patients. This study provides Class II evidence that in patients with AIS and TL undergoing EVT, eCAS is associated with favorable functional outcome at 90 days compared with EVT alone.


  • Influence of Asymptomatic Hemorrhagic Transformation After Endovascular Treatment on Stroke Outcome

    by Marina Guasch-Jiménez, Garbiñe Ezcurra Díaz, Álvaro Lambea-Gil, Anna Ramos-Pachón, Alejandro Martinez-Domeño, Luis Prats-Sanchez, Joan Miquel Fernández-Vidal, Clara Toscano-Prat, Joan Marti-Fabregas, Jose Pablo Martínez-González, et al.

    In patients with acute ischemic stroke (AIS), the impact of hemorrhagic transformation (HT) after endovascular treatment (EVT) on poorer stroke outcome is well established when associated with clinical deterioration. However, the influence of asymptomatic HT remains unclear. We aimed to examine the impact of asymptomatic HT after EVT on functional outcome and mortality. Drawing on Catalan (Spain) population-based prospective stroke registry data, we included patients from 10 comprehensive stroke centers with anterior circulation AIS (2017-2023) who underwent EVT, excluding patients without data on the presence of HT or functional outcome at 3 months of follow-up. HT was categorized as parenchymal hemorrhage (PH), hemorrhagic infarct (HI) types 1 and 2, and remote PH (rPH). Asymptomatic HT was defined as any HT not causing death or the NIH Stroke Scale (NIHSS) score to increase by ≥ 4 points. Functional outcome was centrally assessed using the modified Rankin Scale (mRS). The primary end point was a shift in the 3-month mRS score. After excluding symptomatic intracerebral hemorrhage (sICH), multivariable ordinal regression analyses (adjusted by age, mRS, baseline NIHSS score, baseline Alberta Stroke Program Early CT Score, and modified Thrombolysis In Cerebral Infarction score ≥2b) were performed to test for asymptomatic HT association with the primary end point. We included 3,067 patients (72.0 ± 13.6 years, 50.7% women), 179 (5.8%) with sICH and 612 (20.0%) with asymptomatic HT. HT category frequencies were 8.9% HI1, 7.2% HI2, 4.4% PH1, 3.8% PH2, and 1.5% rPH. The percentage of asymptomatic patients showed a hierarchical distribution, ranging from 93.4% in HI1 to 25.0% in PH2. In the multivariable analysis, asymptomatic HT was associated with poorer outcomes (common odds ratio [cOR] 2.24, 95% CI 1.89-2.66) and higher mortality (adjusted odds ratio 1.50, 95% CI 1.17-1.91). In the sensitivity analyses, the association with functional outcome remained significant for each HT category, with asymptomatic PH2 showing the highest odds of poorer outcomes (cOR 3.15, 95% CI 1.46-6.83). In patients with AIS undergoing EVT, asymptomatic HT was associated with poorer functional outcomes and higher mortality, suggesting that any HT, regardless of its clinical impact or radiologic category, should be considered as an additional EVT safety measure.


  • Leptospirosis‐induced acute acquired inflammatory neuropathy

    by Tomas Xucla‐Ferrarons, Janina Turon‐Sans, Marta Caballero‐Avila, Elena Cortes‐Vicente, Ricard Rojas‐Garcia

    Leptospirosis is a zoonotic infection that can present with neurological manifestations. Although uncommon, it may affect the peripheral nervous system in the form of polyradiculoneuropathy. We report the case of a 30-year-old male who developed flaccid tetraparesis and multiple cranial neuropathies on the fourteenth day of admission to the intensive care unit for fever and multi-organ failure. We also review the existing literature about peripheral nerve damage in leptospirosis and present our hypothesis on the possible pathogenic mechanisms. Electrophysiological findings were consistent with acute demyelinating polyradiculoneuropathy and extensive blood tests were positive for leptospiral IgM and IgG antibodies. Treatment with plasmapheresis was begun, followed by intravenous immunoglobulin (IVIg), and the patient improved slowly. Our work adds to the evidence of leptospirosis infection as a cause of acute demyelinating polyneuropathy. The possibility that leptospirosis-polyradiculoneuropathy may be caused by an immune pathogenesis emphasizes the importance of identifying this entity because immunomodulatory therapy could play a vital role in the recovery process.